. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: J Allergy Clin Immunol. 2021 Mar 2;147(5):1594–1601. doi: 10.1016/j.jaci.2021.01.037

Table III.

PrecISE Primary Outcomes

Primary Outcome	Minimally Detectable Treatment Difference from Placebo (80% Power)
Airway function (FEV₁)^a	4.3% predicted
Symptoms (ACQ-6)^b	0.3 score
Loss of Asthma Control (CompEx)^C	0.66 event rate

FEV₁ measured prior to bronchodilator administration (Assumed SD = 14.5%)

Asthma Control Questionnaire (Assumed SD = 1)

CompEx (Assumed SD = 2)